Roche reported Phase I/II Brainshuttle AD data showing its anti‑amyloid antibody trontinemab (RG6102) achieved rapid and deep amyloid plaque clearance in 91% of participants, with a favorable safety profile and low incidence of ARIA. The antibody uses Roche’s Brainshuttle platform designed to improve blood‑brain barrier transport. The robust imaging responses mark one of Roche’s strongest early Alzheimer’s readouts in years and revive interest in BBB‑shuttled biologics. Roche disclosed the results in company statements and presentations tied to the Brainshuttle AD study (NCT04639050). Clarification: ARIA (amyloid‑related imaging abnormalities) are MRI‑detectable side effects sometimes seen with anti‑amyloid antibodies and are a key safety endpoint in Alzheimer’s trials.